Abstract:<p>Previous studies have demonstrated that targeting inflammation is a promising strategy for treating lipopolysaccharide (LPS)-induced sepsis and related heart injury. Interleukin-35 (IL-35), which consists of two subunits, Epstein–Barr virus-induced gene 3 (EBI3) and p35, is an immunosuppressive cytokine of the IL-12 family and exhibits strong anti-inflammatory activity. However, the role of IL-35 in LPS-induced heart injury reains obscure. In this study, we explored the role of IL-35 in heart injury induced by LPS and its potential mechanisms. Mice were treated with a plasmid encoding IL-35 (pIL-35) and then injected intraperitoneally (ip) with LPS (10 mg/kg). Cardiac function was assessed by echocardiography 12 h later. LPS apparently decreased the expression of EBI3 and p35 and caused cardiac dysfunction and pathological changes, which were significantly improved by pIL-35 pretreatment. Moreover, pIL-35 pretreatment significantly decreased the levels of cardiac proinflammatory cytokines including TNF-α, IL-6, and IL-1β, and the NLRP3 inflammasome. Furthermore, decreased number of apoptotic myocardial cells, increased BCL-2 levels and decreased BAX levels inhibited apoptosis, and LPS-induced upregulation of the expression of cardiac pro-fibrotic genes (MMP2 and MMP9) and fibrotic factor (Collagen type I) was inhibited. Further investigation indicated that pIL-35 pretreatment might suppressed the activation of the cardiac NF-κBp65 and TGF-β1/Smad2/3 signaling pathways in LPS-treated mice. Similar cardioprotective effects of IL-35 pretreatment were observed in mouse myocardial fibroblasts challenged with LPS in vitro. In summary, IL-35 pretreatment can attenuate cardiac inflammation, apoptosis, and fibrotic reactions induced by LPS, implicating IL-35 as a promising therapeutic target in sepsis-related cardiac injury.</p>

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to explore whether interleukin - 35 (IL - 35) pretreatment can alleviate lipopolysaccharide (LPS) - induced cardiac injury and its underlying mechanisms. Specifically, the study aims to evaluate the effects of IL - 35 pretreatment on LPS - induced cardiac inflammation, apoptosis and fibrosis responses. Through in vivo and in vitro experiments, the researchers hope to verify the effectiveness of IL - 35 as a potential target for treating sepsis - related cardiac injury. ### Research Background and Problems - **Sepsis and Its Cardiac Complications**: Sepsis is a common medical emergency in the intensive care unit, affecting more than 30 million people globally every year. Sepsis - induced cardiomyopathy (SIC) is defined as cardiac injury and dysfunction in patients with severe sepsis. Inflammation, oxidative stress, apoptosis and pyroptosis are considered the main pathophysiological features of SIC. - **The Role of LPS**: LPS is an important component of Gram - negative bacteria and can induce sepsis and related cardiac damage. The inflammatory response caused by LPS (such as excessive production of IL - 6, IL - 1β and TNF - α) is considered one of the main mechanisms of LPS - induced cardiac injury. - **The Potential of IL - 35**: IL - 35 is composed of two subunits, namely Epstein - Barr virus - induced gene 3 (EBI3) and p35, and is an immunosuppressive cytokine with strong anti - inflammatory activity. Although IL - 35 has shown a protective effect in various inflammatory and autoimmune diseases, its role in LPS - induced cardiac injury is still unclear. ### Research Objectives - **Evaluating the Effects of IL - 35 Pretreatment**: The researchers hope to evaluate the effects of IL - 35 pretreatment on LPS - induced cardiac injury through in vivo and in vitro experiments, especially its inhibitory effects on inflammation, apoptosis and fibrosis responses. - **Exploring the Underlying Mechanisms**: Further explore the mechanism of IL - 35 pretreatment in LPS - induced cardiac injury, especially its regulatory effects on NF - κB and TGF - β1/Smad2/3 signaling pathways. ### Experimental Design - **Animal Experiments**: Use C57BL/6J mice and divide them into a control group, an LPS group and an LPS + IL - 35 group. Simulate LPS - induced cardiac injury by injecting pIL - 35 plasmid and LPS through the tail vein. - **Cell Experiments**: Culture mouse cardiac fibroblasts (CFs), pretreat them with different concentrations of IL - 35 respectively, and then stimulate them with LPS to evaluate cell viability, inflammatory response and fibrosis response. ### Main Results - **Changes in IL - 35 Expression**: After LPS stimulation, the expression of IL - 35 in mouse cardiac tissue decreased significantly, while pIL - 35 pretreatment significantly increased the expression of IL - 35. - **Cardiac Function and Pathological Changes**: pIL - 35 pretreatment significantly improved LPS - induced cardiac dysfunction and pathological changes, including a decrease in myocardial enzyme levels, an increase in ejection fraction and fractional shortening, and a reduction in myocardial edema and fibrosis response. - **Inhibition of Inflammatory Response**: pIL - 35 pretreatment significantly reduced the levels of pro - inflammatory cytokines (IL - 6, IL - 1β and TNF - α) in LPS - induced cardiac tissue and serum, and inhibited the activation of NLRP3 inflammasome. - **Inhibition of Apoptosis**: pIL - 35 pretreatment significantly reduced LPS - induced cardiomyocyte apoptosis, manifested as a decrease in the number of apoptotic cells and a decrease in the BAX/BCL - 2 ratio. - **Inhibition of Fibrosis Response**: pIL - 35 pretreatment significantly inhibited the expression of fibrosis genes (MMP2 and MMP9) and fibrosis factor (collagen I) in LPS - induced cardiac tissue, and inhibited the activation of TGF - β1/Smad2/3 signaling pathway. ### Conclusion IL - 35 pretreatment can significantly alleviate LPS - induced cardiac injury by inhibiting inflammatory response, apoptosis and fibrosis response, suggesting that IL - 35 may become a potential target for treating sepsis - related cardiac injury.

Interleukin-35 pretreatment attenuates lipopolysaccharide-induced heart injury by inhibition of inflammation, apoptosis and fibrotic reactions

Interleukin-35 inhibits lipopolysaccharide-induced endothelial cell activation by downregulating inflammation and apoptosis

Cardiomyocyte IL-IR2 Protects Heart From Ischemia/Reperfusion Injury by Attenuating NLRP3 Inflammasome Activation and IL-17RA-Mediated Apoptosis

The Protective Role of Interleukin-18 Binding Protein in a Murine Model of Cardiac Ischemia/reperfusion Injury.

Effect of Interleukin-36β on Activating Autophagy of CD4+CD25+ Regulatory T Cells and Its Immune Regulation in Sepsis.

Interleukin-35 Promotes Macrophage Survival and Improves Wound Healing after Myocardial Infarction in Mice.

Pretreatment with interleukin 35-engineered mesenchymal stem cells protected against lipopolysaccharide-induced acute lung injury via pulmonary inflammation suppression

Luteolin Protects Cardiomyocytes Cells against Lipopolysaccharide-Induced Apoptosis and Inflammatory Damage by Modulating Nlrp3

Pretreatment with interleukin-15 attenuates inflammation and apoptosis by inhibiting NF-κB signaling in sepsis-induced myocardial dysfunction

Intermedin 1–53 Protects Cardiac Fibroblasts by Inhibiting NLRP3 Inflammasome Activation During Sepsis

Inhibition of miR-155 Protects Against LPS-induced Cardiac Dysfunction and Apoptosis in Mice

The Anti-inflammatory Mediator Resolvin E1 Protects Mice Against Lipopolysaccharide-Induced Heart Injury

Minocycline alleviates lipopolysaccharide-induced cardiotoxicity by suppressing the NLRP3/Caspase-1 signaling pathway

Pretreatment with Indole-3-Propionic Acid Attenuates Lipopolysaccharide-Induced Cardiac Dysfunction and Inflammation Through the AhR/NF-κB/NLRP3 Pathway

Interleukin-35 ameliorates cardiovascular disease by suppressing inflammatory responses and regulating immune homeostasis

Interleukin-38 ameliorates myocardial Ischemia-Reperfusion injury via inhibition of NLRP3 inflammasome activation in fibroblasts through the IL-1R8/SYK axis

Overexpression of Limb Bud and Heart Alleviates Sepsis-Induced Acute Lung Injury via Inhibiting the NLRP3 Inflammasome

IL-35 (Interleukin-35) Suppresses Endothelial Cell Activation by Inhibiting Mitochondrial Reactive Oxygen Species-Mediated Site-Specific Acetylation of H3K14 (histone 3 Lysine 14).

Interleukin-35 exhibits protective effects in a rat model of hypoxic-ischemic encephalopathy through the inhibition of microglia-mediated inflammation

Abstract 029: Interleukin-35 Suppresses Endothelial Activation by Inhibiting Mitochondrial Reactive Oxygen Species Mediated Site-specific Acetylation of Histone 3 Lysine 14

The Role of IL-33 on LPS-Induced Acute Lung Injury in Mice